Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytokine receptor-like factor 2 (CRLF2), also known as the thymic stromal lymphopoietin receptor (TSLPR), is a type I cytokine receptor subunit that plays a critical role in immune regulation and hematopoiesis. CRLF2 heterodimerizes with the interleukin-7 receptor alpha (IL-7Rα) chain to form a functional high-affinity receptor complex for the cytokine thymic stromal lymphopoietin (TSLP). Upon TSLP binding, the receptor complex activates downstream intracellular signaling cascades, primarily the JAK/STAT (specifically JAK2, STAT3, and STAT5) and PI3K/Akt/mTOR pathways, which promote cell survival, proliferation, and differentiation. Under physiological conditions, CRLF2 is expressed on dendritic cells, monocytes, and other hematopoietic cells, where it drives T helper type 2 (Th2) cell-mediated immune responses.\n\nIn pathological contexts, CRLF2 is heavily implicated in both inflammatory diseases and hematological malignancies. Overexpression or dysregulation of the TSLP/TSLPR axis is a key driver of allergic and inflammatory disorders, including severe asthma, chronic obstructive pulmonary disease (COPD), and chronic rhinosinusitis with nasal polyps (CRSwNP). Furthermore, genetic rearrangements of the CRLF2 gene (such as fusions with IGH or P2RY8) occur in approximately 50% of Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL) and Down syndrome-associated ALL, leading to aberrant cell-surface overexpression of TSLPR and constitutive JAK/STAT activation. Consequently, CRLF2/TSLPR has emerged as a highly promising therapeutic target. Therapeutic strategies include monoclonal antibodies like verekitug that block TSLP binding to treat inflammatory diseases, as well as TSLPR-targeted chimeric antigen receptor (CAR) T-cell therapies (TSLPR-CART) and bispecific antibodies (such as 1B7/CD3) designed to selectively eliminate CRLF2-overexpressing leukemia cells.
Monoclonal antibodies (such as verekitug and RG-7258) act as receptor antagonists by binding to TSLPR/CRLF2, preventing TSLP ligand binding and subsequent activation of downstream JAK/STAT (specifically JAK2, STAT3, STAT5) and PI3K/Akt/mTOR pathways. Chimeric antigen receptor (CAR) T-cell therapies (such as TSLPR-CART) and bispecific antibodies (such as 1B7/CD3) target TSLPR-expressing cells to induce direct T-cell-mediated cytolysis of CRLF2-overexpressing leukemia cells.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytokine receptor-like factor 2 (CRLF2) (CRLF2).